+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
All Ages
All Genders
ID07718724

Evaluating Guideline-Directed Medical Therapy in Uncontrolled Asthma Patients Using Medium- to High-Dose Inhaled Corticosteroids Plus Long-Acting Beta2 Agonists A Prospective Multicenter Cluster-Randomized Trial

Led by AstraZeneca · Updated on 2026-09-24

540

Participants Needed

20

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the impact of Guideline-Directed Medical Therapy GDMT on managing uncontrolled asthma in patients who are already using medium- to high-dose inhaled corticosteroids combined with long-acting beta2 agonists ICS-LABA. This prospective, multicenter, cluster-randomized trial in China aims to assess whether GDMT can improve disease management by guiding physicians and specialized nurses in diagnosis and treatment. The study involves approximately 540 participants across 60 hospitals, with sites randomly assigned to either the intervention or control group to compare usual care with GDMT-guided care. Participants in the intervention group receive care from physicians trained in GDMT protocols, supported by specialized nurses who provide patient education and follow-up reminders. The intervention includes routine training, GDMT education, clinical monitoring every 12 weeks, targeted training, and material revision, all implemented at the hospital level. The control group continues with usual clinical care without additional GDMT intervention. The intervention period lasts up to 48 weeks with follow-up visits every 12 weeks. During the study, participants undergo assessments including demographic data collection, asthma exacerbation monitoring, medication use tracking, asthma control tests ACT scores, lung function tests, quality of life questionnaires SGRQ scores, and medical cost evaluations. Researchers will measure changes in physician behavior, patient outcomes, and healthcare resource use. The primary outcomes focus on the proportion of participants with a written diagnosis of severe asthma at 24 and 48 weeks and the annualized asthma exacerbation rate at 48 weeks.

CONDITIONS

Brief Title

Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here